Home › FDA Ad Comm backs AstraZeneca's lesinurad for gout-associated hyperuricemia
 

Keywords :   


FDA Ad Comm backs AstraZeneca's lesinurad for gout-associated hyperuricemia

2015-10-26 03:18:05| Biotech - Topix.net

The FDA's Arthritis Advisory Committee votes 10-4 recommending approval of AstraZeneca's lesinurad 200 mg tablets, in combination with a xanthine oxidase inhibitor , for the treatment of hyperuricemia associated with gout. The FDA's date is December 29. Lesinurad inhibits a protein called urate transporter which is responsible for most of the renal reabsorption of uric acid.

Tags: comm backs fda astrazenecas

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
04.10Summary for Hurricane Kirk (AT2/AL122024)
04.10Tropical Storm Leslie Public Advisory Number 10
04.10Summary for Tropical Storm Leslie (AT3/AL132024)
More »